What Orlance does

Orlance, Inc. is a Seattle-based, preclinical-stage biotechnology company developing the MACH-1 platform, a needle-free vaccine delivery system that deposits dry, stable RNA-coated gold microparticles directly into skin immune cells — specifically Langerhans cells and dermal dendritic cells — for DNA and RNA vaccine administration. The company's product portfolio is anchored on this single core platform technology, with pipeline candidates including a universal influenza vaccine and a melanoma cancer immunotherapy vaccine, both aimed at Phase 1 clinical trials.

The company is pre-revenue and has been funded entirely through non-dilutive NIH SBIR grants totaling approximately $3.6 million across 2023 and 2024, supporting platform optimization and candidate vaccine development. Its intended go-to-market model is B2B licensing of the MACH-1 platform to pharmaceutical partners for co-development in infectious disease and oncology, with stated end-customers including public health organizations (for pandemic preparedness) and pharmaceutical companies seeking advanced vaccine delivery technologies. Founded in 2016, Orlance operates with 1–10 employees and has no disclosed commercial customers, partnerships outside of NIH/NIAID, or revenue-generating activities.

Name

Orlance

Legal name

Orlance, Inc.

Website

https://orlance.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Orlance is a Seattle-based preclinical biotech developing the MACH-1 needle-free vaccine delivery platform, which uses dry RNA-coated gold microparticles to target skin immune cells. It is building pipeline candidates in universal influenza and melanoma immunotherapy, funded by NIH SBIR grants.

Ownership category

akta.pro rank

Product category

Biotechnology / Vaccine Development

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Needle-Free Injection Systems (Jet Injectors/Microneedle Patches) (HLAHAIAD), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Needle-free vaccine delivery
• RNA vaccine platform
• DNA vaccine technology
• Cancer immunotherapy vaccines
• Infectious disease vaccines

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Vaccine Platform Licensing: Pre-revenue biotech company currently funded through NIH SBIR grants. Expected revenue model involves licensing the MACH-1 platform technology to pharmaceutical partners for vaccine development in infectious diseases and cancer immunotherapy.

Go-to-market motion1 record

Core offering

Orlance develops the MACH-1 needle-free vaccine delivery platform, which uses dry, stable RNA- and DNA-coated gold microparticles to deliver vaccines directly into skin immune cells without needles. The company is advancing pipeline vaccine candidates built on this platform, including a melanoma cancer immunotherapy vaccine and a universal influenza vaccine, with the goal of moving toward Phase 1 clinical trials.

Product overview

Orlance is a Seattle-based biotech company developing a single unified technology platform called MACH-1, a needle-free delivery system for RNA and DNA vaccines. The platform delivers dry, stable RNA-coated gold microparticles directly into skin immune cells. The company's product portfolio centers on this core platform technology, with pipeline products including a melanoma vaccine candidate and a universal influenza vaccine, both currently in development with NIH SBIR grant funding toward Phase 1 clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• MACH-1: Needle-free vaccine delivery platform that delivers dry, stable RNA-coated gold microparticles into the skin for improved vaccine safety, stability, and efficacy.

Products and services

• MACH-1 Platform Needle-free vaccine delivery platform that uses dry, stable RNA- and DNA-coated gold microparticles to deliver vaccines directly into skin immune cells (Langerhans cells and dermal dendritic cells) for improved safety, stability, and efficacy. The platform is intended to be licensed to pharmaceutical and biotech partners for vaccine development in infectious diseases and cancer immunotherapy.
• Melanoma Vaccine Candidate DNA and RNA vaccine delivered via the MACH-1 platform into skin immune cells for cancer immunotherapy targeting melanoma. A pipeline development candidate, currently pre-clinical and funded by NIH SBIR grant support.
• Universal Influenza Vaccine Broad-immunity influenza vaccine candidate built on the MACH-1 needle-free platform, designed to overcome the limitations of current seasonal flu vaccines and provide protection against future pandemic influenza strains. Currently pre-clinical and advancing toward Phase 1 clinical trials.

Quantifiable outcome

• NIH validation through multiple SBIR grants totaling $3.6 million supporting platform development toward Phase 1 clinical trials

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Emerging players

• Vaxxas: Developer of high-density microarray patch (HD-MAP) technology for needle-free vaccine delivery into the skin. Highly comparable on needle-free skin-delivery mechanism and vaccine application, though Vaxxas focuses on patch-format delivery rather than particle-based deposition.
• Micron Biomedical: Developer of dissolvable microneedle array patches for vaccine and drug delivery. Comparable as a needle-free, skin-targeted vaccine delivery company; partial overlap given different delivery format (dissolvable arrays vs. gold microparticles).

Direct peers

• PharmaJet: Needle-free jet injection technology company whose Tropis and Stratis devices deliver vaccines and therapeutics intradermally or intramuscularly without needles. Most directly comparable on the delivery-mechanism axis that defines Orlance's MACH-1 platform.
• Inovio Pharmaceuticals: Clinical-stage DNA vaccine company with proprietary CELLECTRA intradermal electroporation delivery. Comparable because both target skin immune cells for DNA/RNA vaccines against infectious disease and cancer (including HPV-related and oncology indications).
• CureVac: mRNA technology platform company developing prophylactic and therapeutic vaccines. Comparable in RNA platform breadth and infectious-disease focus; Orlance's differentiator is delivery and formulation rather than mRNA chemistry.

Broad incumbents

• Moderna: Dominant mRNA vaccine platform company. Directly comparable because both Moderna and Orlance develop RNA/DNA vaccines, though Moderna operates at vastly greater scale and focuses on lipid nanoparticle delivery rather than needle-free skin delivery.
• BioNTech: Leading mRNA therapeutics company and Pfizer's COVID-19 vaccine partner. Comparable in RNA vaccine modality and infectious-disease/cancer-immunotherapy pipeline focus; differs in delivery technology and scale.
• CSL Seqirus: Major influenza vaccine manufacturer actively pursuing universal and next-generation flu vaccines. Comparable because Orlance's universal influenza program directly competes in this category, and CSL Seqirus is a likely target partner or competitor.
• Pfizer: Global vaccines leader with the Comirnaty mRNA franchise and broad infectious-disease and oncology pipelines. Relevant as both a potential licensing partner for MACH-1 and as the dominant incumbent whose RNA vaccine delivery Orlance seeks to differentiate from.
• Sanofi Pasteur: Global vaccines division developing mRNA, protein subunit, and next-generation influenza and infectious-disease vaccines. Comparable as both a potential licensing/copromotion partner and a strategic competitor pursuing needle-free and intradermal delivery internally.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orlance